Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: Implications for increased vascular risk

Eye

Volumn 12, Issue 2, 1998, Pages 245-251

  Lip, Peck Lin ^a,d   Blann, Andrew D ^b   Jones, Alan F ^c   Lip, Gregory Y H ^b  

^a Wolverhampton Midland Counties E   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^d CITY HOSPITAL   (United Kingdom)

Author keywords

Fibrinogen; Haemorheological factors; Lipoprotein (a); Retinal artery occlusion; Retinal vein occlusion

Indexed keywords

CELL ADHESION MOLECULE; CHOLESTEROL; D DIMER; FIBRIN; FIBRINOGEN; HEMOGLOBIN; LIPID; LIPOPROTEIN A; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD RHEOLOGY; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; MALE; PLASMA VISCOSITY; RETINA ARTERY OCCLUSION; RETINA BLOOD VESSEL OCCLUSION; RETINA VEIN OCCLUSION; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION;

EID: 0031776393     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/eye.1998.58     Document Type: Article

References (39)

1. Vine AK, Samama MM. The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. Surv Ophthalmol 1993;37:283-92.
2. Lowe GDO. Blood rheology in arterial disease. Clin Sci 1986,71:137-46.
3. Lip GYH, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994;8:693-702.
4. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
5. Lip GYH. Fibrinogen and cardiovascular disease. Q J Med 1995;88:155-65.
6. Lip GYH, Blann AD. von Willebrand factor and its relevance to cardiovascular disorders. Br Heart J 1995;74:580-3.
7. Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci 1995;89:205-14.
8. Lip GYH, Jones AF. Lipoprotein (a) and vascular disease: thrombogenesis and atherogenesis. Q J Med 1995;88:529-39.
9. Wu KK. Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med 1996;239:17.
10. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator inhibitor in atherosclerosis. Thromb Haemostat 1995;74:626-30.
11. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, Boisseau M. Plasma thrombomodulin: a new approach of endothelial damage. Int Angio 1993;12:355-9.
12. Lavin MJ, Dhillon BJ. Cyclic variation in onset of CRVO. Br J Ophthalmol 1987;71:18-20.
13. Woodhouse F, Khaw KT, Meade TW, Stirling Y, Plummer M. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994;343:435-9.
14. Klein BA. Occlusion of the central retinal vein: clinical importance of certain histo-pathologic observations. Am J Ophthalmol 1953;36:316-24.
15. Rabinowicz IM, Litman S, Michaelson IC. Branch venous thrombosis: a pathological report. Trans Ophthalmol Soc UK 1968;88:191-210.
16. Smit RL, Baarsma GS, Koudstaal PJ. The source of embolism in amaurosis fugax and retinal artery occlusion. Int Ophthalmol 1994;18:83-6.
17. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions: a case-control study. Ophthalmology 1992;99:509-14.
18. Dodson PM, Kritzinger EE. Underlying medical conditions in young patients and ethnic differences in retinal vein occlusion. Trans Ophthalmol Soc UK 1985;104:114-9.
19. Appiah AP, Trempe CL. Risk factors associated with branch vs central retinal vein occlusion. Ann Ophthalmol 1989;21:153-7.
20. Greven CM, Slusher MM, Weaver RG. Retinal arterial occlusions in young adults. Am J Ophthalmol 1995;120:776-83.
21. Snyers B, Serckx JP. [Occlusion of the central retinal vein in young adults: risk factors and visual prognosis]. Bull Soc Belge Ophthalmol 1993;250:51-8 (in French).
22. Arend O, Remky A, Jung F, Kiesewetter H, Reim M, Wolf S. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996;103:80-6.
23. Mansour AM, Walsh JB, Henkind P. Mortality and morbidity in patients with central retinal vein occlusion. Ophthalmologica 1992;204:199-204.
24. Hankey GJ, Slattery JM, Warlow CP. Prognosis and prognostic factors of retinal infarction: a prospective cohort study. BMJ 1991;302:499-504.
25. Bandello F, Vigano D'Angelo S, Parlavecchia M, et al. Hypercoagulability and high lipoprotein (a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994;72:39-43.
26. Pimenov IV, Zaitseva NS, Volkolakova RI. [Hemostasis in patients with diseases of the retina and uveal tract]. Vestnik Oftalmologii 1992;108:27-30 (in Russian).
27. Piermarocchi S, Segato T, Bertoja H, et al. Branch retinal vein occlusion: the pathogenic role of blood viscosity. Ann Ophthalmol 1990;22:303-11.
28. Glacet-Bernard A, Chabanel A, Lelong F, Samama MM, Coscas G. Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors. Ophthalmology 1994;101:1483-7.
29. Williamson TH, Rumley A, Lowe GDO. Blood viscosity, coagulation and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996;80:203-8.
30. Wiek J, Krause M, Schade M, Wiederholt M, Hansen LL. Haemorheological parameters in patients with retinal artery occlusion and anterior ischaemic optic neuropathy. Br J Ophthalmol 1992;76:142-5.
31. Wiek J, Schade M, Wiederholt M, Arntz HR, Hansen LL. Haemorheological changes in patients with retinal vein occlusion after isovolaemic haemodilution. Br J Ophthalmol 1990;74:665-9.
32. Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993;342:84-6.
33. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentrations of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994;90:2236-40.
34. Lowe GDO, Rumley A, Yarnell JWG, Sweetnam PM, Thomas HF. Fibrin D-dimer, von Willebrand factor and tissue plasminogen activator antigens are predictors of major ischaemic heart disease: the Caerphilly study. Blood Coag Fibrinolys 1995;6:156-7.
35. Muller HM, Diekstall FF, Schmidt E, Marz W, Canzler H, Demeler U. Lipoprotein (a): a risk factor for retinal vascular occlusion. Ger J Ophthalmol 1992;1:338-41.
36. Tavola A, D'Angelo SV, Bandello F, et al. Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein (a) levels: a case report. Thromb Res 1995;80:327-31.
37. Glacet-Bernard A, Bayani N, Chretien P, Cochard C, Lelong F, Coscas G. Antiphospholipid antibodies in retinal vascular occlusion: a prospective study of 75 patients. Arch Ophthalmol 1994;112:790-5.
38. Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993;115:162-7.
39. Murray PI, Young DW, Aggarwal RK, Blann AD. Von Willebrand factor, endothelial damage and ocular disease. Ocular Immunol Inflamm 1993;1:315-22.